Literature DB >> 10831200

Cardiovascular responses to anesthetic induction in patients chronically treated with angiotensin-converting enzyme inhibitors.

M Licker1, A Schweizer, L Höhn, C Farinelli, D R Morel.   

Abstract

PURPOSE: To investigate the effects of chronic ACE inhibition on cardiac neural function following induction of general anesthesia in patients with underlying coronary artery disease.
METHOD: In a prospective case-control study, heart rate variability (HRV) and baroreflex control were compared preoperatively and 30 min after anesthesia induction in patients receiving, or not, ACEI (n=16, control group and n=16, ACEI group). All patients had normal cardiac function and anesthesia consisted of a fixed dose regimen of fentanyl and midazolam. Anesthesia-related hypotension was defined by systolic blood pressure < 90 mmHg. Spectral density of HRV was calculated for low frequency and high frequency bands (LF, from 0.05 to 0.15 Hz and HF, from > 0.15 to 0.6 Hz). Baroreflex sensitivity was estimated after blood pressure changes induced by injections of phenylephrine (PHE) and nitroglycerin (NTG).
RESULTS: The HRV parameters and baroreflex sensitivity were not different between groups, during the awake and anesthesia periods. Anesthesia produced similar reduction in total HRV in the Control and ACEI groups (-93 +/- 28% vs -89 +/- 32%), and in baroreflex sensitivity during NTG (-64 +/- 21% vs -54 +/- 17%) or PHE tests (-74 +/- 25% vs -72 +/- 22%). Anesthesia-related hypotension occurred in nine patients in the ACEI group (vs two controls). Although the hypertensive response to phenylephrine was greater after anesthesia in both groups, the sensitivity to phenylephrine was attenuated in those patients experiencing hypotension in the ACEI group.
CONCLUSIONS: Chronic preoperative treatment with ACEIs does not influence cardiac autonomic regulation and anesthetic-induced hypotensive episodes are mainly attributed to decreased alpha-adrenergic vasoconstrictive response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831200     DOI: 10.1007/BF03018973

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

1.  Risk assessment and outcomes of vasoplegia after cardiac surgery.

Authors:  Athanasios Tsiouris; Lynn Wilson; Ala S Haddadin; James J Yun; Abeel A Mangi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-13

2.  [Pre-operative measurement of heart rate variability in diabetics: a method to estimate blood pressure stability during anaesthesia induction].

Authors:  D Knüttgen; S Trojan; M Weber; M Wolf; F Wappler
Journal:  Anaesthesist       Date:  2005-05       Impact factor: 1.041

Review 3.  [Valvular heart disease: anesthesia in non-cardiac surgery].

Authors:  H Mutlak; M Humpich; K Zacharowski; R Lehmann; D Meininger
Journal:  Anaesthesist       Date:  2011-09       Impact factor: 1.041

4.  [Preoperative administration of angiotensin-converting enzyme inhibitors].

Authors:  U Schirmer; W Schürmann
Journal:  Anaesthesist       Date:  2007-06       Impact factor: 1.041

Review 5.  Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.

Authors:  Zui Zou; Hong B Yuan; Bo Yang; Fengying Xu; Xiao Y Chen; Guan J Liu; Xue Y Shi
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

6.  Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis.

Authors:  Qiong Ling; Yu Gu; Jiaxin Chen; Yansheng Chen; Yongyong Shi; Gaofeng Zhao; Qianqian Zhu
Journal:  BMC Anesthesiol       Date:  2018-02-26       Impact factor: 2.217

7.  Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.

Authors:  Sean van Diepen; Colleen M Norris; Yinggan Zheng; Jayan Nagendran; Michelle M Graham; Damaris Gaete Ortega; Derek R Townsend; Justin A Ezekowitz; Sean M Bagshaw
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.